Literature DB >> 18504281

Management of the controversial aspects of the antiphospholipid syndrome pregnancies: a guide for clinicians and researchers.

D Erkan1, S Patel, M Nuzzo, M Gerosa, P L Meroni, A Tincani, M D Lockshin.   

Abstract

BACKGROUND: Recommendations for the treatment of aPL-positive patients with pregnancy morbidity are based on a limited number of well-designed clinical trials. However, the management of pregnant aPL-positive women still displays several open questions.
OBJECTIVE: To determine the practice patterns of experienced physicians in the management of the controversial aspects of aPL pregnancies.
METHODS: A questionnaire reproducing debated conditions was initially sent to the Advisory Board members (ABMs) of the 12th Congress of aPL and the Fifth Conference on Sex Hormones, Pregnancy and Rheumatic Diseases (Florence, Italy, April 2007), and then the same questionnaire was posted at the Hospital for Special Surgery (www.hss.edu) website and all attendees (ATS) of the above meetings were invited to participate via e-mail. Answers have been collected and analysed in a descriptive fashion and responses of the two groups evaluated by Chi-square or Fisher's exact test.
RESULTS: As a whole 75 responses from the ABMs and ATS were included in the analysis. In general, there was no significant difference between the opinions of two groups.
CONCLUSIONS: Management recommendations displayed reasonable consistence: (i) for the use of low-dose aspirin and low-molecular weight heparin during pregnancy and during ovarian stimulation for in vitro fertilization; (ii) against oestrogen-containing oral contraceptives; and (iii) for the use of anticoagulants in the post-partum period.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18504281     DOI: 10.1093/rheumatology/ken181

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  15 in total

1.  Pregnancy and catastrophic antiphospholipid syndrome.

Authors:  Jose A Gómez-Puerta; Jose Sanin-Blair; Claudio Galarza-Maldonado
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

2.  25 years of the antiphospholipid syndrome: lights and shadows on the primary prophylaxis of asymptomatic patients with confirmed positivity of antiphospholipid antibodies.

Authors:  Laura Andreoli; Angela Tincani
Journal:  Intern Emerg Med       Date:  2009-01-08       Impact factor: 3.397

3.  Aspirin in asymptomatic patients with confirmed positivity of antiphospholipid antibodies? Yes (in some cases).

Authors:  Maria Gerosa; Cecilia Chighizola; Pier Luigi Meroni
Journal:  Intern Emerg Med       Date:  2008-07-01       Impact factor: 3.397

4.  Management of antiphospholipid syndrome.

Authors:  Nicoletta Del Papa; Nikoleta Vaso
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-08       Impact factor: 5.346

Review 5.  [Antiphospholipid syndrome].

Authors:  C Specker
Journal:  Z Rheumatol       Date:  2016-08       Impact factor: 1.372

6.  [Antiphospholipid syndrome].

Authors:  C Specker
Journal:  Z Rheumatol       Date:  2015-04       Impact factor: 1.372

Review 7.  Current treatment of antiphospholipid syndrome: lights and shadows.

Authors:  Gerard Espinosa; Ricard Cervera
Journal:  Nat Rev Rheumatol       Date:  2015-06-30       Impact factor: 20.543

Review 8.  Update on Antiphospholipid Syndrome: Ten Topics in 2017.

Authors:  Ilaria Cavazzana; Laura Andreoli; Maarteen Limper; Franco Franceschini; Angela Tincani
Journal:  Curr Rheumatol Rep       Date:  2018-03-15       Impact factor: 4.592

9.  When conventional treatment fails: the role of intravenous immunoglobulin in recurrent pregnancy loss secondary to antiphospholipid syndrome.

Authors:  Jacklyn Chay; Karin Lust; Paul Kubler; Leonie Callaway
Journal:  Obstet Med       Date:  2013-05-03

Review 10.  New approaches for managing antiphospholipid syndrome.

Authors:  Doruk Erkan; Michael D Lockshin
Journal:  Nat Clin Pract Rheumatol       Date:  2009-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.